Severe Refractory Asthma: an Update

Overview

Journal Eur Respir Rev

Specialty Pulmonary Medicine

Date 2013 Sep 3

PMID 23997049

Citations 20

Authors

Reinier R L Wener

Elisabeth H Bel

Affiliations

Soon will be listed here.

Abstract

Asthma is a heterogeneous disease in which adequate asthma control cannot be achieved in a substantial proportion despite currently available treatment possibilities. This subgroup has been defined as "severe refractory" asthma. Over the past years considerable progress has been made regarding a more exact definition of severe refractory asthma. A systematic approach to evaluate the asthma patient has been postulated. Further detailed classification into distinct phenotypes is ongoing to target the right treatment to the right patient. And, new therapeutic targeted treatment options are currently in development to provide possible new targets to improve disease state, symptoms and quality of life. This review will provide an update on the latest advancements with regard to all these domains.

Citing Articles

Migrasomes derived from human umbilical cord mesenchymal stem cells: a new therapeutic agent for ovalbumin-induced asthma in mice.

Gu W, Zheng T, Li W, Luo X, Xu X, Wang Y Stem Cell Res Ther. 2025; 16(1):26.

PMID: 39865246 PMC: 11770983. DOI: 10.1186/s13287-025-04145-4.

Nebulization of Hypoxic hUCMSC-EVs Attenuates Airway Epithelial Barrier Defects in Chronic Asthma Mice by Transferring CAV-1.

Luo X, Wang Y, Mao Y, Xu X, Gu W, Li W Int J Nanomedicine. 2024; 19:10941-10959.

PMID: 39493276 PMC: 11531287. DOI: 10.2147/IJN.S476151.

The new biologic drugs: Which children with asthma should get what?.

Hillson K, Saglani S, Bush A Pediatr Pulmonol. 2024; 59(12):3057-3074.

PMID: 39267467 PMC: 11601016. DOI: 10.1002/ppul.27218.

A non-invasive strategy for suppressing asthmatic airway inflammation and remodeling: Inhalation of nebulized hypoxic hUCMSC-derived extracellular vesicles.

Xu X, Wang Y, Luo X, Gao X, Gu W, Ma Y Front Immunol. 2023; 14:1150971.

PMID: 37090722 PMC: 10113478. DOI: 10.3389/fimmu.2023.1150971.

The Role of CD4 T Cells and Microbiota in the Pathogenesis of Asthma.

Jeong J, Lee H Int J Mol Sci. 2021; 22(21).

PMID: 34769255 PMC: 8584410. DOI: 10.3390/ijms222111822.

References

Peters S, Kunselman S, Icitovic N, Moore W, Pascual R, Ameredes B . Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med. 2010; 363(18):1715-26. PMC: 3011177. DOI: 10.1056/NEJMoa1008770. View

Castro M, Mathur S, Hargreave F, Boulet L, Xie F, Young J . Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011; 184(10):1125-32. DOI: 10.1164/rccm.201103-0396OC. View

Baptist A, Reddy R . Inhaled corticosteroids for asthma: are they all the same?. J Clin Pharm Ther. 2009; 34(1):1-12. DOI: 10.1111/j.1365-2710.2008.00970.x. View

Mortimer K, Tata L, Smith C, West J, Harrison T, Tattersfield A . Oral and inhaled corticosteroids and adrenal insufficiency: a case-control study. Thorax. 2006; 61(5):405-8. PMC: 2111185. DOI: 10.1136/thx.2005.052456. View

Corren J, Lemanske R, Hanania N, Korenblat P, Parsey M, Arron J . Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011; 365(12):1088-98. DOI: 10.1056/NEJMoa1106469. View

Pavord I, Korn S, Howarth P, Bleecker E, Buhl R, Keene O . Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012; 380(9842):651-9. DOI: 10.1016/S0140-6736(12)60988-X. View

Cazzola M, Calzetta L, Matera M . β(2) -adrenoceptor agonists: current and future direction. Br J Pharmacol. 2011; 163(1):4-17. PMC: 3085864. DOI: 10.1111/j.1476-5381.2011.01216.x. View

Hashimoto S, Ten Brinke A, Roldaan A, van Veen I, Moller G, Sont J . Internet-based tapering of oral corticosteroids in severe asthma: a pragmatic randomised controlled trial. Thorax. 2011; 66(6):514-20. DOI: 10.1136/thx.2010.153411. View

Robinson D, Campbell D, Durham S, Pfeffer J, Barnes P, Chung K . Systematic assessment of difficult-to-treat asthma. Eur Respir J. 2003; 22(3):478-83. DOI: 10.1183/09031936.03.00017003. View

10.

Luyster F, Teodorescu M, Bleecker E, Busse W, Calhoun W, Castro M . Sleep quality and asthma control and quality of life in non-severe and severe asthma. Sleep Breath. 2011; 16(4):1129-37. PMC: 3617495. DOI: 10.1007/s11325-011-0616-8. View

11.

Moore W, Bleecker E, Curran-Everett D, Erzurum S, Ameredes B, Bacharier L . Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol. 2007; 119(2):405-13. PMC: 2837934. DOI: 10.1016/j.jaci.2006.11.639. View

12.

Thomson N, Rubin A, Niven R, Corris P, Siersted H, Olivenstein R . Long-term (5 year) safety of bronchial thermoplasty: Asthma Intervention Research (AIR) trial. BMC Pulm Med. 2011; 11:8. PMC: 3045390. DOI: 10.1186/1471-2466-11-8. View

13.

Cox G, Thomson N, Rubin A, Niven R, Corris P, Siersted H . Asthma control during the year after bronchial thermoplasty. N Engl J Med. 2007; 356(13):1327-37. DOI: 10.1056/NEJMoa064707. View

14.

Siroux V, Basagana X, Boudier A, Pin I, Garcia-Aymerich J, Vesin A . Identifying adult asthma phenotypes using a clustering approach. Eur Respir J. 2011; 38(2):310-7. DOI: 10.1183/09031936.00120810. View

15.

Berry M, Hargadon B, Shelley M, Parker D, Shaw D, Green R . Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med. 2006; 354(7):697-708. DOI: 10.1056/NEJMoa050580. View

16.

Sears M, Taylor D, Print C, Lake D, Li Q, Flannery E . Regular inhaled beta-agonist treatment in bronchial asthma. Lancet. 1990; 336(8728):1391-6. DOI: 10.1016/0140-6736(90)93098-a. View

17.

Dixon A, Pratley R, Forgione P, Kaminsky D, Whittaker-Leclair L, Griffes L . Effects of obesity and bariatric surgery on airway hyperresponsiveness, asthma control, and inflammation. J Allergy Clin Immunol. 2011; 128(3):508-15.e1-2. PMC: 3164923. DOI: 10.1016/j.jaci.2011.06.009. View

18.

Evans D, Cullinan P, Geddes D . Cyclosporin as an oral corticosteroid sparing agent in stable asthma. Cochrane Database Syst Rev. 2001; (2):CD002993. PMC: 8407285. DOI: 10.1002/14651858.CD002993. View

19.

Adams N, Bestall J, Jones P, Lasserson T, Griffiths B, Cates C . Fluticasone at different doses for chronic asthma in adults and children. Cochrane Database Syst Rev. 2008; (4):CD003534. PMC: 6984662. DOI: 10.1002/14651858.CD003534.pub3. View

20.

Moore W, Meyers D, Wenzel S, Teague W, Li H, Li X . Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med. 2009; 181(4):315-23. PMC: 2822971. DOI: 10.1164/rccm.200906-0896OC. View